ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5309-5317

  Stohr, Bradley A ^a   Blackburn, Elizabeth H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CAMPTOTHECIN; PROTEIN P53; RNA; TELOMERASE; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TELOMERASE RNA; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA SEQUENCE; TELOMERE; WILD TYPE; APOPTOSIS; CELL CULTURE; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; GENE FUSION; GENETIC TRANSFECTION; GENETICS; MUTATION; NEOPLASM; NUCLEOTIDE REPEAT; PATHOLOGY; PHYSIOLOGY; SUICIDE TRANSGENE; TRANSGENE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE FUSION; GENES, P53; GENES, TRANSGENIC, SUICIDE; HUMANS; MUTATION; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; REPETITIVE SEQUENCES, NUCLEIC ACID; RNA; RNA, SMALL INTERFERING; TELOMERASE; TELOMERE; TRANSFECTION; TRANSGENES; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 48549084245     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0504     Document Type: Article

References (48)

1. Blackburn EH. Telomere states and cell fates. Nature 2000;408:53-6.
2. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005;19:2100-10.
3. Levy MZ, Allsopp RC, Futcher AB, Greider CW, Harley CB. Telomere end-replication problem and cell aging. J Mol Biol 1992;225:951-60.
4. Hahn WC. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003;21:2034-43.
5. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004;14:501-13.
6. Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577-84.
7. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, Blackburn EH. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci U S A 2001;98:7982-7.
8. Blackburn EH. Telomerase and cancer: Kirk A. Landon - AACR prize for basic cancer research lecture. Mol Cancer Res 2005;3:477-82.
9. Marusic L, Anton M, Tidy A, Wang P, Villeponteau B, Bacchetti S. Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability. Mol Cell Biol 1997;17:6394-401.
10. Guiducci C, Cerone MA, Bacchetti S. Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 2001;20:714-25.
11. Xu L, Blackburn EH. Human Rif1 protein binds aberrant telomeres and aligns along anaphase midzone microtubules. J Cell Biol 2004;167:819-30.
12. Li S, Crothers J, Haqq CM, Blackburn EH. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 2005;280:23709-17.
13. Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 2004;64:4833-40.
14. Shay JW, Wright WE. Telomeres are double-strand DNA breaks hidden from DNA damage responses. Mol Cell 2004;14:420-1.
15. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
16. Goudsouzian LK, Tuzon CT, Zakian VA. S. cerevisiae Tel1p and Mre11p are required for normal levels of Est1p and Est2p telomere association. Mol Cell 2006;24:603-10.
17. Wu Y, Xiao S, Zhu XD. MRE11-RAD50-NBS1 and ATM function as co-mediators of TRF1 in telomere length control. Nat Struct Mol Biol 2007;14:832-40.
18. Chan SW, Chang J, Prescott J, Blackburn EH. Altering telomere structure allows telomerase to act in yeast lacking ATM kinases. Curr Biol 2001;11:1240-50.
19. Chan SW, Blackburn EH. Telomerase and ATM/Tel1p protect telomeres from nonhomologous end joining. Mol Cell 2003;11:1379-87.
20. Metcalfe JA, Parkhill J, Campbell L, et al. Accelerated telomere shortening in ataxia telangiectasia. Nat Genet 1996;13:350-3.
21. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007;448:1068-71.
22. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316:1160-6.
23. Zhou BB, Anderson HJ, Roberge M. Targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther 2003;2:S16-22.
24. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9.
25. Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol 2003;14:938-45.
26. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-4.
27. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003;13:1549-56.
28. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999;283:1321-5.
29. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-5.
30. Li J, Stern DF. Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 2005;280:12041-50.
31. Wang J, Wiltshire T, Wang Y, et al. ATM-dependent CHK2 activation induced by anticancer agent, irofulven. J Biol Chem 2004;279:39584-92.
32. Xu L, Blackburn EH. Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres. Mol Cell 2007;28:315-27.
33. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
34. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7.
35. Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res 2006;66:5763-71.
36. Lau A, Swinbank KM, Ahmed PS, et al. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005;7:493-500.
37. Hector RE, Shtofman RL, Ray A, et al. Tel1p preferentially associates with short telomeres to stimulate their elongation. Mol Cell 2007;27:851-8.
38. Cooper MJ, Haluschak JJ, Johnson D, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994;6:569-79.
39. McEachern MJ, Iyer S, Fulton TB, Blackburn EH. Telomere fusions caused by mutating the terminal region of telomeric DNA. Proc Natl Acad Sci U S A 2000;97:11409-14.
40. Kirk KE, Harmon BP, Reichardt IK, Sedat JW, Blackburn EH. Block in anaphase chromosome separation caused by a telomerase template mutation. Science 1997;275:1478-81.
41. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005;26:867-74.
42. Jeggo PA, Lobrich M. Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair (Amst) 2006;5:1192-8.
43. Guo X, Deng Y, Lin Y, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J 2007;26:4709-19.
44. Million RP. Impact of genetic diagnostics on drug development strategy. Nat Rev Drug Discov 2006;5:459-62.
45. Hall J. The ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants. Cancer Lett 2005;227:105-14.
46. Fang NY, Greiner TC, Weisenburger DD, et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A 2003;100:5372-7.
47. Yu GL, Bradley JD, Attardi LD, Blackburn EH. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature 1990;344:126-32.
48. Lin J, Smith DL, Blackburn EH. Mutant telomere sequences lead to impaired chromosome separation and a unique checkpoint response. Mol Biol Cell 2004;15:1623-34.